 Tuberculosis, Multidrug-Resistant
"Tuberculosis, Multidrug-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
| Descriptor ID |
D018088
|
| MeSH Number(s) |
C01.252.410.040.552.846.775
|
| Concept/Terms |
Tuberculosis, Multidrug-Resistant- Tuberculosis, Multidrug-Resistant
- Multidrug-Resistant Tuberculosis
- Tuberculosis, Multidrug Resistant
- Tuberculosis, MDR
- MDR Tuberculosis
- Tuberculosis, Multi-Drug Resistant
- Multi-Drug Resistant Tuberculosis
- Tuberculosis, Multi Drug Resistant
|
Below are MeSH descriptors whose meaning is more general than "Tuberculosis, Multidrug-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Tuberculosis, Multidrug-Resistant".
This graph shows the total number of publications written about "Tuberculosis, Multidrug-Resistant" by people in this website by year, and whether "Tuberculosis, Multidrug-Resistant" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 | | 2002 | 1 | 1 | 2 | | 2004 | 1 | 0 | 1 | | 2006 | 0 | 1 | 1 | | 2008 | 2 | 1 | 3 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 6 | 0 | 6 | | 2013 | 3 | 0 | 3 | | 2014 | 2 | 0 | 2 | | 2016 | 5 | 2 | 7 | | 2017 | 3 | 0 | 3 | | 2018 | 7 | 0 | 7 | | 2019 | 2 | 2 | 4 | | 2020 | 1 | 1 | 2 | | 2021 | 1 | 0 | 1 | | 2022 | 1 | 0 | 1 | | 2024 | 1 | 1 | 2 | | 2025 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Tuberculosis, Multidrug-Resistant" by people in Profiles.
-
Hughes JA, Pinilla M, Brooks KM, Eke AC, Stek A, Best BM, Mirochnick M, Browning R, Wiesner L, George K, Knowles K, De Koker P, Ngocho JS, Fairlie L, Chakhtoura N, Hesseling AC, Decloedt E, Shapiro DE, van Schalkwyk M. Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s. Clin Pharmacokinet. 2025 Apr; 64(4):619-630.
-
Kaur P, Chaisson LH, Kiragu ZW, Buddadhumaruk P, Austin AF, Gao Y, Wirtz VJ, Arbeit RD, Fetalvero KB, Nguyen HB, Nguyen NV, Ha H, Eisenach K, Walter ND, Mitnick CD, Gler MTS, Phan H, Nahid P, Phillips PPJ, Horsburgh CR, Vel?squez GE. Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial. Contemp Clin Trials. 2025 May; 152:107875.
-
Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, Schaaf HS, Seddon JA, Furin J, Achar J, Radke K, Sachs T, Abubakirov A, Ahmed S, Akkerman OW, Al Ani NA, Amanullah F, Ahmad N, Anderson LF, Asfaw M, Bango F, Bauer T, Becerra M, Boeree M, Brinkmann F, Brown R, Brust J, Campbell JR, Carvalho AC, Carvalho I, Cegielski JP, Centis R, Chan ED, Chauhan S, Chiang SS, Chan PC, D'Ambrosio L, Dalcolmo M, Daneilyan N, de Vries G, Draper HR, Fairlie L, Francis JR, Franke M, Gegia M, Restrepo CG, Guenther A, Gureva T, Haecker B, Harausz E, Hewison C, Hicks RM, Huerga H, Hughes J, Isaakidis P, Kadri SM, Khan MA, Kotrikadze T, Kuksa L, Lachenal N, Lange C, Lecca L, Lopez-Varela E, Lucena S, Mariandyshev A, Mattoo S, Mendez-Echevarria A, Migliori GB, Mitnick C, Mohr-Holland E, Mulanda W, Murzabakova T, Myrzalieve B, Ndjeka N, Niemann S, Ozere I, Padayatchi N, Parmar M, Parpieva N, Manzur-Ul-Alam M, Rybak N, Sachdeva KS, Salmon K, Santiago-Garcia B, Schaub D, Shah I, Shah S, Shah V, Sharma S, Shim TS, Shin S, Sinha A, Skrahina A, Solanki H, Solans BP, Soriano-Arandes A, Toktogonova A, van der Werf T, Vel?squez GE, Williams B, Yim JJ, Savic R, Hesseling A. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025 02; 9(2):100-111.
-
Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, Kendall EA, Davies G, Brigden G, Churchyard G, Cirillo DM, Di Meco E, Gopinath R, Mitnick C, Scott C, Amanullah F, Bansbach C, Boeree M, Campbell M, Conradie F, Crook A, Daley CL, Dheda K, Diacon A, Gebhard A, Hanna D, Heinrich N, Hesseling A, Holtzman D, Jachym M, Kim P, Lange C, McKenna L, Meintjes G, Ndjeka N, Nhung NV, Nyang'wa BT, Paton NI, Rao R, Rich M, Savic R, Schoeman I, Makokotlela BS, Spigelman M, Sun E, Svensson E, Tisile P, Varaine F, Vernon A, Diul MY, Kasaeva T, Zignol M, Gegia M, Mirzayev F, Schumacher SG. Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
-
Hoffman CJ, France T, Cram T, Bodmer JL, Sanders JS. Pediatric Multidrug-Resistant Disseminated Tuberculosis Presenting as Small Finger Tuberculous Osteomyelitis: A Case Report. JBJS Case Connect. 2024 01 01; 14(1).
-
Campbell JR, Chan ED, Falzon D, Trajman A, Keshavjee S, Leung CC, Miller AC, Monedero-Recuero I, Rodrigues DS, Seo H, Baghaei P, Udwadia Z, Viiklepp P, Bastos M, Menzies D. Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis. Clin Infect Dis. 2022 12 19; 75(12):2201-2210.
-
Johara FT, Benedetti A, Platt R, Menzies D, Viiklepp P, Schaaf S, Chan E. Evaluating the performance of propensity score matching based approaches in individual patient data meta-analysis. BMC Med Res Methodol. 2021 11 23; 21(1):257.
-
Kwak N, Winters N, Campbell JR, Chan ED, Gegia M, Lange C, Lee M, Milanov V, Menzies D, Yim JJ. Changes in treatment for multidrug-resistant tuberculosis according to national income. Eur Respir J. 2020 11; 56(5).
-
Jain P, Garing S, Verma D, Saranathan R, Clute-Reinig N, Gadwa J, Peterson C, Hermansky G, Astashkina Fernandez A, Asare E, Weisbrod TR, Spencer E, Mulholland CV, Berney M, Bell D, Nichols KP, Le Ny AM, Ordway D, Jacobs WR, Somoskovi A, Minch KJ. Nanoluciferase Reporter Mycobacteriophage for Sensitive and Rapid Detection of Mycobacterium tuberculosis Drug Susceptibility. J Bacteriol. 2020 10 22; 202(22).
-
Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019 11 15; 200(10):e93-e142.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|